NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HD-17-021 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-17-031 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit the Center for International Blood and Marrow Transplant Research (CIBMTR) a limited competition application for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.
Funding Opportunity PA-17-459 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Funding Opportunity PAR-17-460 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Funding Opportunity PAR-17-458 from the NIH Guide for Grants and Contracts. The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website (https://doi.org/10.3886/Series606).
Funding Opportunity RFA-DK-17-509 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.
Funding Opportunity RFA-DK-17-510 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and built a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in HDS implicated in liver toxicity. This RFA and companion RFA-DK-17-509 will seek the continuation of the Data Coordinating Center and six Clinical Centers
Notice NOT-HG-17-015 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-534 from the NIH Guide for Grants and Contracts
Notice to Extend the Expiration Date for PAR-15-195 "NeuroNEXT Infrastructure Resource Access (X01)"
Notice NOT-NS-18-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-099 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-456 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).
Funding Opportunity PAR-17-457 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.
Notice NOT-MH-17-043 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-455 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Allergy and infectious Diseases (NIAID) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in NIAID mission areas.
Notice NOT-HL-17-351 from the NIH Guide for Grants and Contracts
Notice NOT-ES-17-007 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-042 from the NIH Guide for Grants and Contracts
Notice NOT-DA-17-053 from the NIH Guide for Grants and Contracts
Notice NOT-NR-17-025 from the NIH Guide for Grants and Contracts